NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

RevImmune

T-CELL TECHNOLOGY & DEVELOPMENT

CEO: Linda Powers
https://dirigeant.societe.com/dirigeant/Linda.POWERS.29622905.html


*Our COVID-19 Program

1. We believe IL-7 (CYT107) can prevent patients who are in the hospital for COVID-19 from progressing to having to be treated in the ICU or progressing to needing more than 4L/minute of supplemental oxygen.

2. Both the underlying biology and existing data from CYT107 clinical trials and compassionate use support this belief.

• The biology underlying progression into the ICU is severe and progressive lymphopenia [see figure from Lancet article on ALC in survivors and non-survivors of COVID-19] and a large body of literature has established that IL-7 resolves lymphopenia by expanding T cell populations.
• Data from clinical use of CYT107 have shown encouraging results in sepsis and a variety of viral diseases (PML, HIV, HCV, etc.) – resolving the condition or preventing clinical decline.

3. CYT107 is one of the few potential new treatment options already in advanced clinical development – currently in Phase IIB trials, with accumulated safety data in >440 patients showing an excellent safety profile, and with efficacy data in both sepsis and multiple viral diseases.

https://www.revimmune.com/
https://www.revimmune.com/covid-19-program

Compassionate Use and Clinical Trials of CYT107 for COVID-19

Compassionate use access to CYT107 is being provided to certain hospitals in Italy, Spain, France, Belgium and the US while the clinical trial is being prepared and launched.